The value of S-phase and DNA ploidy analysis as prognostic markers for node-negative breast cancer in the Australian setting

被引:9
作者
Wong, SWJ [1 ]
Rangan, AM
Bilous, AM
Boyages, J
Gebski, V
Benson, EM
机构
[1] Westmead Hosp, Dept Immunopathol, Inst Clin Pathol & Med Res, Westmead, NSW 2145, Australia
[2] Westmead Hosp, Dept Pathol Anat, Westmead, NSW 2145, Australia
[3] Westmead Hosp, Inst Clin Pathol & Med Res, New S Wales Breast Canc Inst, Westmead, NSW 2145, Australia
[4] Westmead Hosp, Dept Radiat Oncol, Westmead, NSW 2145, Australia
[5] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW 2006, Australia
关键词
DNA flow cytometry; DNA ploidy; node-negative breast cancer; S-phase fraction;
D O I
10.1080/003130299105241
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
This study aimed to determine the prognostic significance of DNA ploidy and S-phase fraction (SPF) measurements in our laboratory for patients with node-negative breast cancer. Frozen tumors from axillary node-negative breast cancer patients (n = 50) treated at Westmead Hospital, NSW, between 1988 and 1991 were analysed by flow cytometry. The median duration of follow-up for all patients was 8.4 years. Forty-six specimens provided evaluable DNA histograms with 43% (n = 20) diploid and 56% (n = 26) aneuploid tumors identified. Comparisons of DNA ploidy status and SPF were made with traditional prognostic variables, which included age, menopausal status, tumor size, histologic grade and hormone receptor status, Our results showed that there was no significant difference in disease-free or overall survival between patients with diploid and aneuploid tumors. Histologic grade 3 tumors were more likely to be aneuploid and had higher SPF than grade 1 or 2 tumors. Patients with grade 3 tumors and a high SPF were four times more likely to relapse than the rest of the population. These results indicate that DNA flow cytometric analysis in our laboratory provides additional prognostic data that could be utilised alongside traditional clinical and histopathologic indicators for predicting outcome for patients.
引用
收藏
页码:90 / 94
页数:5
相关论文
共 40 条
[1]  
BAUER KD, 1993, 3 AUSTR FLOW CYTOMET
[2]  
BILOUS AM, 1987, PATHOLOGY, V19, P223
[3]  
BOSARI S, 1992, CANCER-AM CANCER SOC, V70, P1943, DOI 10.1002/1097-0142(19921001)70:7<1943::AID-CNCR2820700722>3.0.CO
[4]  
2-Y
[5]   PREDICTION OF RELAPSE OR SURVIVAL IN PATIENTS WITH NODE-NEGATIVE BREAST-CANCER BY DNA FLOW-CYTOMETRY [J].
CLARK, GM ;
DRESSLER, LG ;
OWENS, MA ;
POUNDS, G ;
OLDAKER, T ;
MCGUIRE, WL .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (10) :627-633
[6]   PROGNOSTIC-SIGNIFICANCE OF S-PHASE FRACTION IN GOOD-RISK, NODE-NEGATIVE BREAST-CANCER PATIENTS [J].
CLARK, GM ;
MATHIEU, MC ;
OWENS, MA ;
DRESSLER, LG ;
EUDEY, L ;
TORMEY, DC ;
OSBORNE, CK ;
GILCHRIST, KW ;
MANSOUR, EG ;
ABELOFF, MD ;
MCGUIRE, WL .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (03) :428-432
[7]   DNA PLOIDY AND SURVIVAL IN BREAST-CANCER PATIENTS [J].
CORNELISSE, CJ ;
VANDEVELDE, CJH ;
CASPERS, RJC ;
MOOLENAAR, AJ ;
HERMANS, J .
CYTOMETRY, 1987, 8 (02) :225-234
[8]  
DRESSLER LG, 1988, CANCER, V61, P420, DOI 10.1002/1097-0142(19880201)61:3<420::AID-CNCR2820610303>3.0.CO
[9]  
2-0
[10]  
DRESSLER LG, 1993, J CELL BIOCHEM, V176, P212